Projects per year
Personal profile
Research Strategic Pillar
Dr. Randall Urban, VP and Chief Research Officer, has determined that UTMB research should be prioritized into six health communities. This researcher has received the following badge(s):
Research Strategic Pillar Keywords
- Infectious/ Immunological Health
Fingerprint
Dive into the research topics where Richard Rupp is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 4-arm study to investigate the mixed vaccination schedules of a 21-valent pneumococcal conjugate vaccine and a 20-valent pneumococcal conjugate vaccine in healthy infants an
Rupp, R. (PI)
7/19/24 → 7/18/29
Project: Research project
-
A Phase 2, Randomized, Double-Blind Trial to Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Infants
Rupp, R. (PI)
6/28/24 → 6/27/27
Project: Research project
-
Phase III, randomized, single-blind, placebo-controlled, multi-center study to evaluate non-interference of concomitant administration of routine pediatric vaccines on the antibody response of an investigational live-attenuated respiratory syncytial viru
Rupp, R. (PI)
5/8/24 → 5/7/29
Project: Research project
-
Progress with COVID vaccine development and implementation
Titball, R. W., Bernstein, D. I., Fanget, N. V. J., Hall, R. A., Longet, S., MacAry, P. A., Rupp, R. E., van Gils, M., von Messling, V., Walker, D. H. & Barrett, A. D. T., Apr 1 2024, In: npj Vaccines. 9, 1, p. 69 69.Research output: Contribution to journal › Editorial › peer-review
Open Access -
Safety, tolerability and immunogenicity of a novel 24-valent pneumococcal vaccine in toddlers: A phase 1 randomized controlled trial
Borys, D., Rupp, R., Smulders, R., Chichili, G. R., Kovanda, L. L., Santos, V., Malinoski, F., Siber, G., Malley, R. & Sebastian, S., Apr 11 2024, In: Vaccine. 42, 10, p. 2560-2571 12 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial
the DMID 17-0090 Study Group, Feb 15 2024, In: Journal of Infectious Diseases. 229, 2, p. 327-340 14 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine
Ye, X., Shih, D. J. H., Ku, Z., Hong, J., Barrett, D. F., Rupp, R. E., Zhang, N., Fu, T. M., Zheng, W. J. & An, Z., Apr 1 2024, In: npj Vaccines. 9, 1, p. 70 70.Research output: Contribution to journal › Article › peer-review
Open Access -
A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)
for the V114-029 PNEU-PED study group, Jan 27 2023, In: Vaccine. 41, 5, p. 1142-1152 11 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations